WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317148
CAS#: 917393-39-6
Description: Lorediplon is a nonbenzodiazepine of the pyrazolopyrimidine family that is being pursued as a treatment for insomnia but has not completed development. Lorediplon demonstrated a dose-dependent improvement in sleep, whereas zolpidem showed a more sustained WASO effect. No next-day hangover effects were observed. These sleep effects are also consistent with the pharmacokinetic profile of lorediplon. These results warrant clinical trials in patients with insomnia.
MedKoo Cat#: 317148
Name: Lorediplon
CAS#: 917393-39-6
Chemical Formula: C20H15FN4O2S
Exact Mass: 394.08997
Molecular Weight: 394.42
Elemental Analysis: C, 60.90; H, 3.83; F, 4.82; N, 14.21; O, 8.11; S, 8.13
Synonym: Lorediplon
IUPAC/Chemical Name: N-[2-fluoro-5-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-N-methylacetamide
InChi Key: NQPOCLFSADOXBR-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H15FN4O2S/c1-12(26)24(2)17-10-13(5-6-15(17)21)16-7-8-22-20-14(11-23-25(16)20)19(27)18-4-3-9-28-18/h3-11H,1-2H3
SMILES Code: CC(N(C1=CC(C2=CC=NC3=C(C(C4=CC=CS4)=O)C=NN23)=CC=C1F)C)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 394.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Zisapel N. Current Phase II investigational therapies for insomnia. Expert
Opin Investig Drugs. 2015 Mar;24(3):401-11. doi: 10.1517/13543784.2015.987340.
Epub 2014 Nov 25. Review. PubMed PMID: 25423562.
2: Horoszok L, Baleeiro T, D'Aniello F, Gropper S, Santos B, Guglietta A, Roth T.
A single-dose, randomized, double-blind, double dummy, placebo and
positive-controlled, five-way cross-over study to assess the pharmacodynamic
effects of lorediplon in a phase advance model of insomnia in healthy Caucasian
adult male subjects. Hum Psychopharmacol. 2014 May;29(3):266-73. doi:
10.1002/hup.2395. PubMed PMID: 24911577.
